References
- Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporos Int 1992;2:285-9.
- Oden A, Dawson A, Dere W, Johnell O, Johnson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603.
- Poor G, Atkinson EJ, Lewallen DG, O'Fallon WM, Melton III LJ. Age related hip fractures in men: clinical spectrum and short-term outcome. Osteoporos Int 1995;5:419-26.
- Kanis JA, Johnell O, Oden A, Lindsay RL, Wahner HW, Dunn WL, Calvo MJ, Harris TB, Heyse SP. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:669-74.
- Looker AC, Orwoll ES, Johnston CC Jr, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Johnsson B. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8.
- Kaštelan D, Kujundžić Tiljak M, Kraljević I, Kardum I, Giljević Z, Koršić M. Calcaneus ultrasound in males - normative data in the Croatian population (ECUM study). J Endocrinol Invest 2006;29:221-5.
- Frost ML, Blake GM, Fogelman I. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int 2000;11:321-30.
- De Laet CEDH, van Hout BA, Burger H, Weel AEAM, Hofman A, Pols HAP. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-93.
- Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J. Bone density variation and its effect on risk of vertebral deformity in men and women studied in thirteen european Centres: the EVOS Study. J Bone Miner Res 1997;12:1883-94.
- Anderson FH, Francis RM, Selby PL, Cooper C. Sex hormones and osteoporosis in men. Calcif Tissue Int 1998;62:185-8.
- Orwoll ES. Androgens. U: Bilezikian JP, Raisz LG, Rodan GR, urednici. Principles of Bone Biology. San Diego: Academic Press; 1996.
- Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1989;95:2886-95.
- Gori F, Hofbauer LC, Conover CA, Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 1999;140:5579-86.
- Khosla S, Melton III LJ, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002;87:1443-50.
- Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly man. J Clin Endocrinol Metab 1999;84:3626-35.
- Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 2003;32:25-38.
- Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990;8:612-7.
- Kalender WA, Felsenberg D, Louis O. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur J Radiol 1989;9:75-80.
- Aaron JE, Makins NB, Sagreiy K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987;215:260-71.
- Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004;75:100-9.
- Ruff CB, Hayes WC. Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 1988;6:886-96.
- Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84:3431-4.
- Kaštelan D, Giljević Z, Aganović I, Koršić M. Osteoporoza u muškaraca. Liječ Vjesn 2004;126:71-6.
- Ferrari S, Manen D, Bonjour JP, Slosman D, Rizzoli R. Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 1999;84:2043-8.
- Peris P, Alvarez L, Oriola J, Guanabens N, Monegal A, de Osaba MJ, Jo J, Pons F, Bellesta AM, Munoz-Gomez J. Collagen type 1 alpha 1 gene polymorphism in idiopathic osteoporosis in men. Rheumatology 2000;39:1222-5.
- Kaštelan D, Grubić Z, Kraljević I, Đurić K, Kardum I, Dušek T, Štingl K, Giljević Z, Kerhin-Brkljačić V, Suchanek E, Koršić M. Decreased peak bone mass is associated with a 3-bp deletion/insertion of the CYP19 intron 4 polymorphism: a preliminary data from the GOOS study. J Endocrinol Invest (u tisku).
- Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
- Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998;49:803-9.
- Zmuda MJ, Cauley JA, Kuller LH, Ferrell RE. Androgen receptor CAG repeat length is associated with icreased hip bone loss and vertebral fracture risk among older men. J Bone Miner Res 2000;15(Suppl 1):491.
- Scane AC, Francis RM. Risk factors for osteoporosis in men. Clin Endocrinol 1993;38:15-6.
- Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly man. J Clin Endocrinol Metab 1999;84:3626-35.
- Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Maskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
- Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
- Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni Mj, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344-52.
- Neer RM, Arnaud CD, Zanchetta JR, Prince L, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.
- Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5.
- Orwoll ES, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. New Engl J Med 2000;343:604-10.
- Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
- Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
- Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1897-9.
- Finkelstein JS, Hayes A, Hunzelman JL, Wyland SS, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New Engl J Med 2003;349:1216-26.
- Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A. Osteoporosis in hypogonadal men: Role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 1986;7:261-8.
- Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.
- Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
- Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-8.
- Dalton JT, Mukherjee A, Zhu Z, Kirkovski L, Miller DD. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244:1-4.
- Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003;26:1563-9.
- Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology (u tisku).
- Kaštelan D, Giljević Z, Kraljević I, Koršić M. Selective estrogen receptor modulators: a possible new treatment of osteoporosis in males. Med Hypotheses 2006;67:1052-3.
- Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841-6.
- Kaštelan D, Koršić M. New hopes in the treatment of osteoporosis in men. Future Rheumatol (u tisku).
- Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiaition and activation. Cell 1998;93:165-76.
- Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64.
- Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.
- Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5.
- Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005;25:4946-55.
- Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 supresses tumor-induced bone resorption and multiple myeloma growth in vivo.Blood (u tisku).
- Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Catham JA. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35:828-35.
- Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76.
- Beighton P, Barnard A, Hamersma H, van der Wouden A. The syndromic status of sclerosteosis and Van Buchem disease. Clin Genet 1984;25:175-81.
- Warnington K, Morony S, Sarosi I. Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. U: 27th Annual Meeting of the American Society of Bone and Mineral Research; 23-27 Sep 2005. Nashville (TN), SAD. Sažetak.
- Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang JM, Tomaszek T, Yamashita DS, Marquis RW, Ol H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo monkeys. Bone (u tisku).